Published: 2017-01-23

Levetiracetam monotherapy effect on serum calcium and serum vitamin D in patient of epilepsy

Anubha Garg, Surekha Dabla, Sandeep Nagenhalli, Sanjay Fotedar


Background: Objective of the study was to determine the Levetiracetam monotherapy effect on serum calcium and serum vitamin D levels in tertiary care hospital in Haryana, India.

Methods: A total of 110 patients with epilepsy, were enrolled to the study for one year between April 2013 to August 2014. All male patients aged 15-60 years and premenopausal females with epilepsy were included in the study. The study was a interventional prospective study design. The antiepileptic drug levetiracetam was administered starting from a dose of 20 mg/kg and dose was titrated according to the clinical response. During the follow up period, the subjects were asked about the seizure frequency and other side effects. The patients were be subjected to questionnaires based proforma. Baseline investigations, Hemogram, renal and liver function tests, calcium, phosphate, vitamin D and bone mineral density and T scores were noted. All investigations were repeated after one year of levetiracetam monotherapy.

Results: The mean age of onset of seizures in the study group was 23.22±6.62 years. 58% (n=29) were seizure free after 1 year of levetiracetam monotherapy, 28% patients had adequate control and 14% patients had poor control of their seizure episodes. There was an insignificant change in Hemoglobin, total leukocyte count, platelet count, renal parameters and Liver enzymes from baseline over a year of levetiracetam therapy. Serum calcium levels increased insignificantly from baseline levels of 9.68±0.59 mg/dl to 9.72±0.56mg/dl. Vitamin D levels increased from baseline of 39.35±14.91ng/ml to 39.84±14.07 ng/ml. Bone mineral density increased insignificantly from baseline of 0.92±0.13 g/cm2 to 0.93±0.13 g/cm2.

Conclusions: Present study has shown an overall beneficial effect on serum calcium, Vitamin D level, bone mineral density and T scores on DEXA scan.


Epilepsy, Monotherapy, Seizure control, Vitamin D

Full Text:



Christiansen C, Rodbro P, Lund M. Incidence of anticonvulsant osteomalacia and effect of vitamin D: controlled therapeutic trial. BMJ. 1973;4:695-70.

Tolman KG, Jubiz W, Sannella JJ, Madsen JA, Belsey RE, Goldsmith RS, et al. Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children. Pediatrics. 1975;56:45-51.

Hahn TJ, Hendin BA, Scharp CR, Boissaeu VC, Haddad JG. Serum 25-hydroxycholcalciferol levels and bone mass in patients on chronic anticonvulsant therapy. N Engl J Med. 1975;292:550-3.

Richens A, Rowe DJF. Disturbance of calcium metabolism by anticonvulsant drugs. BMJ. 1970;4:73-6.

Kim SH, Lee JW, Choi KG, Chung HW, Lee HW. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav. 2007;10(2):291-5.

Abou K, Paula H, Privitera MD. An open-label study of levetiracetam at individualized doses between 1000 and 3000 mg/dayin adult patients with refractory epilepsy. Seizure. 2003;12(3):141-9.

Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik l. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 2000;55(2):236-42.

Lyseng-Williamson KA. Levetiracetam: a review of its use in epilepsy. Drugs. 2011;71(4):489-514.

Elinor BM, Eric G. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure. 2003;12:131-5.

Taoufik MA, Catherine T. Levetiracetammono therapy for newly diagnosed epilepsy patients. Seizure. 2003;12:154-6.

Tim B, Helen Y, Lyn G, Mary B. Clinical experience of marketed Levetiracetam in an epilepsy clinic- a one year follow up study. Seizure. 2003;12:136-40.

McTague A, Kneen R, Kumar R, Spinty S, Appleton R et al. Intravenous levetiracetam in acute repetitive seizures and status epilepticus in children: Experience from a children’s hospital. Seizure. 2012;21:529-34.

Koo DL, Joo EY, Kim D, Hong SB. Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy. Epilepsy Res. 2013;104-34.

Nissen-Meyer LS, Svalheim S, Taubøll E, Reppe S, Lekva T, Solberg LB, et al. Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism. Epilepsia. 2007;48:1850-60.

Ali II, Herial NA, Horrigan T, Kellough L, Tietjen GE. Measurement of bone mineral density in patients on levetiracetammonotherapy. Am Epilepsy SocAbstr. 2006;2:150.

Andras H, Zsofia C, Peter L. Epilepsy and Vitamin D. Inter J Neuro. 2013;00(00):1-7.

Chifari R, Testolin C, Canevini MP, Piazzini A, Gambardella A, Viri M, et al. Increased risk of decreased bone density in adults receiving long-term antiepileptic therapy. Epilepsia. 2003;44:276.

Svalheim S, Taubøll E, Dahl E, Aleksandersen M, McNeilly A, Ropstad E, et al. Levetiracetam affects gonadotropin levels and peripheral sex steroid hormones in female Wistar rats. Epilepsia. 2005;46:189